Cargando…

Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer

SIMPLE SUMMARY: We have discovered that immunoglobulins digested with plasmin, one of the enzymes of blood clotting cascade acquire a capability to bind to one of the chains of plasminogen. We investigate here the mechanisms and localization of such binding. We also show that levels of this digested...

Descripción completa

Detalles Bibliográficos
Autores principales: Lokshin, Anna, Mikhaleva, Lyudmila M., Goufman, Eugene I., Boltovskaya, Marina N., Tikhonova, Natalia B., Stepanova, Irina I., Stepanov, Alexandr A., Potoldykova, Natalia V., Vinarov, Andrey Z., Stemmer, Paul, Iakovlev, Vasily
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389667/
https://www.ncbi.nlm.nih.gov/pubmed/34440049
http://dx.doi.org/10.3390/biology10080817
_version_ 1783742911959007232
author Lokshin, Anna
Mikhaleva, Lyudmila M.
Goufman, Eugene I.
Boltovskaya, Marina N.
Tikhonova, Natalia B.
Stepanova, Irina I.
Stepanov, Alexandr A.
Potoldykova, Natalia V.
Vinarov, Andrey Z.
Stemmer, Paul
Iakovlev, Vasily
author_facet Lokshin, Anna
Mikhaleva, Lyudmila M.
Goufman, Eugene I.
Boltovskaya, Marina N.
Tikhonova, Natalia B.
Stepanova, Irina I.
Stepanov, Alexandr A.
Potoldykova, Natalia V.
Vinarov, Andrey Z.
Stemmer, Paul
Iakovlev, Vasily
author_sort Lokshin, Anna
collection PubMed
description SIMPLE SUMMARY: We have discovered that immunoglobulins digested with plasmin, one of the enzymes of blood clotting cascade acquire a capability to bind to one of the chains of plasminogen. We investigate here the mechanisms and localization of such binding. We also show that levels of this digested immunoglobulin molecule are higher in patients with prostate cancer. Therefore, this digested immunoglobulin could serve as a biomarker for the detection of patients with prostate cancer from patients with benign prostate hyperplasia. We observed that the diagnostic accuracy of blood levels of digested immunoglobulins is dramatically higher than that of PSA. ABSTRACT: The differential diagnosis of prostate cancer is problematic due to the lack of markers with high diagnostic accuracy. We previously demonstrated the increased binding of IgG to human plasminogen (PLG) in plasma of patients with prostate cancer (PC) compared to healthy controls. Heavy and light chains of PLG (PLG-H and PLG-L) were immobilized on 96-well plates and the binding of IgG to PLG-H and PLG-L was analyzed in serum from 30 prostate cancer (PC) patients, 30 patients with benign prostatic hyperplasia (BPH) and 30 healthy controls using enzyme-linked immunosorbent assay (ELISA). Our results demonstrate that IgG from PC sera bind to PLG-H but not to PLG-L. This interaction occurred through the free IgG C-terminal lysine (Lys) that becomes exposed as a result of IgG conformational changes associated with proteolysis. Circulating levels of modified IgG with exposed C-terminal Lys (IgG-Lys) were significantly higher in PC patients than in healthy controls and in BPH. We used Receiver Operating Characteristic (ROC) analysis to calculate the sensitivity (SN) and specificity (SP) of circulating IgG-Lys for differentiating PC from BPH as 77% and 90%, respectively. The area under the curve (AUC) was 0.87. We demonstrated that the diagnostic accuracy of circulating levels of IgG-Lys is much higher than diagnostic accuracy of total PSA (tPSA).
format Online
Article
Text
id pubmed-8389667
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83896672021-08-27 Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer Lokshin, Anna Mikhaleva, Lyudmila M. Goufman, Eugene I. Boltovskaya, Marina N. Tikhonova, Natalia B. Stepanova, Irina I. Stepanov, Alexandr A. Potoldykova, Natalia V. Vinarov, Andrey Z. Stemmer, Paul Iakovlev, Vasily Biology (Basel) Article SIMPLE SUMMARY: We have discovered that immunoglobulins digested with plasmin, one of the enzymes of blood clotting cascade acquire a capability to bind to one of the chains of plasminogen. We investigate here the mechanisms and localization of such binding. We also show that levels of this digested immunoglobulin molecule are higher in patients with prostate cancer. Therefore, this digested immunoglobulin could serve as a biomarker for the detection of patients with prostate cancer from patients with benign prostate hyperplasia. We observed that the diagnostic accuracy of blood levels of digested immunoglobulins is dramatically higher than that of PSA. ABSTRACT: The differential diagnosis of prostate cancer is problematic due to the lack of markers with high diagnostic accuracy. We previously demonstrated the increased binding of IgG to human plasminogen (PLG) in plasma of patients with prostate cancer (PC) compared to healthy controls. Heavy and light chains of PLG (PLG-H and PLG-L) were immobilized on 96-well plates and the binding of IgG to PLG-H and PLG-L was analyzed in serum from 30 prostate cancer (PC) patients, 30 patients with benign prostatic hyperplasia (BPH) and 30 healthy controls using enzyme-linked immunosorbent assay (ELISA). Our results demonstrate that IgG from PC sera bind to PLG-H but not to PLG-L. This interaction occurred through the free IgG C-terminal lysine (Lys) that becomes exposed as a result of IgG conformational changes associated with proteolysis. Circulating levels of modified IgG with exposed C-terminal Lys (IgG-Lys) were significantly higher in PC patients than in healthy controls and in BPH. We used Receiver Operating Characteristic (ROC) analysis to calculate the sensitivity (SN) and specificity (SP) of circulating IgG-Lys for differentiating PC from BPH as 77% and 90%, respectively. The area under the curve (AUC) was 0.87. We demonstrated that the diagnostic accuracy of circulating levels of IgG-Lys is much higher than diagnostic accuracy of total PSA (tPSA). MDPI 2021-08-23 /pmc/articles/PMC8389667/ /pubmed/34440049 http://dx.doi.org/10.3390/biology10080817 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lokshin, Anna
Mikhaleva, Lyudmila M.
Goufman, Eugene I.
Boltovskaya, Marina N.
Tikhonova, Natalia B.
Stepanova, Irina I.
Stepanov, Alexandr A.
Potoldykova, Natalia V.
Vinarov, Andrey Z.
Stemmer, Paul
Iakovlev, Vasily
Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title_full Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title_fullStr Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title_full_unstemmed Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title_short Proteolyzed Variant of IgG with Free C-Terminal Lysine as a Biomarker of Prostate Cancer
title_sort proteolyzed variant of igg with free c-terminal lysine as a biomarker of prostate cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389667/
https://www.ncbi.nlm.nih.gov/pubmed/34440049
http://dx.doi.org/10.3390/biology10080817
work_keys_str_mv AT lokshinanna proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT mikhalevalyudmilam proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT goufmaneugenei proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT boltovskayamarinan proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT tikhonovanataliab proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT stepanovairinai proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT stepanovalexandra proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT potoldykovanataliav proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT vinarovandreyz proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT stemmerpaul proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer
AT iakovlevvasily proteolyzedvariantofiggwithfreecterminallysineasabiomarkerofprostatecancer